Device Trial Radar · NCT07171060
Laplace Early Feasibility Study - Canada
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jun 18, 2024
Primary completion
Dec 30, 2027
Study completion Jan 1, 2032
Sponsor
- Lead sponsor
- Laplace Interventional, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 12, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 60 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to assess the safety and technical feasibility of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
Conditions
- Tricuspid Regurgitation
Interventions
Laplace TTVR SystemDevice
Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of severe, symptomatic tricuspid regurgitation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Technical successTime frame: During procedure
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Ottawa Heart Institute
Ottawa, Ontario, Canada · Recruiting
Sunnybrook Research Institute
Toronto, Ontario, Canada · Recruiting
St. Michael's Hospital
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.